Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2005-03-15
2005-03-15
Fredman, Jeffrey (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093200, C424S093210, C424S093300, C514S04400A, C435S069100, C435S320100, C435S325000, C435S455000
Reexamination Certificate
active
06866842
ABSTRACT:
The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
REFERENCES:
patent: 5053050 (1991-10-01), Itay
patent: 5130141 (1992-07-01), Law et al.
patent: 5336263 (1994-08-01), Ersek et al.
patent: 5516532 (1996-05-01), Atala et al.
patent: 5538722 (1996-07-01), Blau et al.
patent: 5594032 (1997-01-01), Gonzalez-Cadavid et al.
patent: 5667778 (1997-09-01), Atala
patent: 5833978 (1998-11-01), Tremblay
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: WO 9618303 (1986-06-01), None
patent: WO 9107992 (1991-06-01), None
patent: WO 9407999 (1994-04-01), None
patent: WO 9421299 (1994-09-01), None
patent: WO 9836055 (1998-08-01), None
patent: WO 9947163 (1999-09-01), None
Huard et al Gene Therapy 9:1617-1625, 2002.*
Newman et al Am J Nurs. 103(8):46-55, 2003.*
Rosenberg et al, Gene Therapist, Heal Thyself. Science 287:1751, 2000.*
Verma, Gene Therapy: beyond 2000. Mol. Ther.. 1:493, 2000.*
Friedmann, Principles for Human Gene Therapy Studies. Science 287(5461):2163-5, 2000.*
Anderson WF, Human Gene Therapy. Nature 392:25-30, 1998.*
M. Reza Dana et al., “Interleukin-1 Receptor Antagonist Suppresses Langerhans Cell Activity and Promotes Ocular Immune Privilege”,Investigative Ophthalmology&Visual Science, 1998, 39:70-77.
G. Ferrari et al., “Muscle Regeneration by Bone Marrow-Derived Myogenic Progenitors”,Science, 1998, 279:1528-1530.
E. Barr and J. Leiden, “Systemic Delivery of Recombinant Proteins by Genetically Modified Myoblasts”,Science, 1991, 254:1507-1509.
T. Katagiri et al., “Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage”,J. Cell Biology, 1994, 127:1755-1766.
T.A. Rando and H. Blau, “Primary Mouse Myoblast Purification, Characterization, and Transplantation for Cell-mediated Gene Therapy”,J. Cell Biology, 1994, 125:1275-1287.
T. Yokoyama et al., “Gene Therapy as a Potential Treatment for BPH; Injection of Myoblast-Adenovirus Transfected with Human Inductible Nitric Oxide Synthase (iNOS) into the Proximal Urethra”,J. Urology, 1999, 161 (4) Supplement:305 (Abstract 1775).
J. Huard et al., “Hyoblast Injection into the Bladder Wall: A Possible Method of Modulating Detrusor Contractility and Cell-Mediated Gene Therapy for Bladder Dysfunction”,J. Urology, 1998, 159 (5) Supplement:16 (Abstract 62).
J. Huard et al., “Nitric Oxide Synthase (NOS) Gene Therapy for Erectile Dysfunction; Comparison Between Plasmid, Adenovirus and Adenovirus Transduced Myoblast Vectors”,J. Urology, 1998, 159:90 (Abstract 342).
TA. Rando et al., 1994, “Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy”, Journal of Cell Biology, 125:1275-1287.
Z. Qu et al., 1998, “Development of approaches to improve cell survival in myoblast transfer therapy”, Journal of cell Biology, 142:1257-1267.
J. Huard et al., 1992, “Human myoblast transplantation: preliminary results of 4 cases”, Muscle and Nerve, 15:550-560.
CS Day et al., 1997, “Myoblast-mediated gene transfer to the joint”, Journal of Orthopedic Research, 15:894-903.
G. Bandara et al., 1993, “Inarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer”, Proc. Natl. Acad. Sci. USA, 90:10764-10768.
G. Acsadi et al., 1994, “A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity”, Human Molecular Genetics, 3:579-584.
C. Kasemkijwattana et al., 1998, “Development of approaches to improve the healing following muscle contusion”, Cell Transplantation, 7:585-598.
KP Spindler et al., 1995, “Regional mitotic response of the meniscus to platelet-derived growth factor (PDGF-AB)”, Journal of Orthopedic Research, 13:201-207.
Gussoni et al., 1992, “Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation”, Nature, 356:435-438.
Karpati et al., 1993, “Myoblast transfer in Duchenne muscular dystrophy”, Annals of Neurology, 34:8-17.
Tremblay et al., 1993, “Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy”, Cell Transplantation, 2:99-112.
Huard 1994, “High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice”, Journal of Clinical Investigation, 93:586-599.
Huard 1994, “Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection”, Muscle and Nerve 17:224-234.
Huard 1995, “The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants”, Gene Therapy, 2:107-115.
Chancellor Michael B.
Huard Johnny
Fredman Jeffrey
Kaushal Sumesh
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
University of Pittsburgh
LandOfFree
Muscle-derived cells (MDCs) for treating muscle-or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muscle-derived cells (MDCs) for treating muscle-or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscle-derived cells (MDCs) for treating muscle-or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375484